Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.

@article{Fernndez2015TenofovirentecavirMA,
  title={Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.},
  author={Inmaculada Berlanga Fern{\'a}ndez and Carmelo Loinaz and Olga Ocon Hernandez and Manuel Abradelo and Adolfo Edison Manrique and Javier Fernandez Calvo and Marisa Manzano and Alvaro Tejerizo Garc{\'i}a and F{\'e}lix Cambra and Gregorio Castellano and Carlos Jim{\'e}nez},
  journal={Transplant infectious disease : an official journal of the Transplantation Society},
  year={2015},
  volume={17 5},
  pages={
          695-701
        }
}
BACKGROUND AND AIMS Combination of hepatitis B immunoglobulin (HBIG) and a nucleos(t)ide analog (NA) is considered the standard of care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, use of lifelong HBIG has significant limitations. We evaluated the efficacy and safety of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) after withdrawal of HBIG in patients who had been under HBIG-regimen prophylaxis post LT. METHODS Patients at low risk… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Similar Papers

Loading similar papers…